Edgestream Partners L.P. Purchases 119,183 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Edgestream Partners L.P. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 734.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,403 shares of the biopharmaceutical company's stock after acquiring an additional 119,183 shares during the period. Edgestream Partners L.P. owned approximately 0.11% of Halozyme Therapeutics worth $8,640,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. Raymond James Financial Inc. bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $21,838,000. Avantax Advisory Services Inc. boosted its holdings in Halozyme Therapeutics by 23.2% in the fourth quarter. Avantax Advisory Services Inc. now owns 9,766 shares of the biopharmaceutical company's stock worth $467,000 after purchasing an additional 1,839 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Halozyme Therapeutics in the fourth quarter worth approximately $1,958,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter worth approximately $29,000. Finally, Royce & Associates LP boosted its holdings in Halozyme Therapeutics by 58.9% in the fourth quarter. Royce & Associates LP now owns 196,999 shares of the biopharmaceutical company's stock worth $9,419,000 after purchasing an additional 72,988 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00. Following the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $41,403,763.17. The trade was a 2.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director directly owned 28,611 shares of the company's stock, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,497 shares of company stock worth $3,533,884. Insiders own 2.40% of the company's stock.

Analyst Ratings Changes

HALO has been the topic of several research reports. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price on the stock. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the stock a "neutral" rating in a report on Wednesday. Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Finally, Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a report on Tuesday, May 13th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Hold" and a consensus target price of $62.70.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock traded down $0.20 on Thursday, hitting $57.81. 1,110,490 shares of the company's stock were exchanged, compared to its average volume of 1,751,853. The company has a 50-day simple moving average of $54.48 and a 200-day simple moving average of $57.15. The stock has a market capitalization of $7.12 billion, a PE ratio of 15.38, a PEG ratio of 0.39 and a beta of 1.15. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The company had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same quarter in the previous year, the company earned $0.79 EPS. Halozyme Therapeutics's revenue for the quarter was up 35.2% on a year-over-year basis. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.